



## ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

January 24, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 24, 2019-- [ImmunoGen, Inc.](http://www.immunogen.com), (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business.

### Conference Call Information

To access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be accessed through the Investors section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the webcast, a replay of the call will be available at the same location through February 22, 2019.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now." Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FR $\alpha$ )-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMG779 and IMG632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190124005187/en/>

Source: ImmunoGen, Inc.

### INVESTOR RELATIONS CONTACT

Sarah Kiely  
781-895-0600  
[sarah.kiely@immunogen.com](mailto:sarah.kiely@immunogen.com)

OR

THRUST Strategic Communications  
Chelcie Lister  
910-777-3049  
[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

### MEDIA CONTACT

Courtney O'Konek  
781-895-0600  
[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting  
Robert Stanislaro  
212-850-5657  
[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)